Absci rises on Phase 1 ABS-201 update and $100 million raise
Absci Corporation shares rose Wednesday. The AI drug maker showed early safety data for ABS-201, its candidate antibody for pattern hair loss, and set a $100 million stock offering to pay for further trials.